Clinical Trial Update: A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• ASP7991

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED